Thymosin alpha 1 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-09-30 and is reviewed periodically as new material appears.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
| Property | Value | Notes |
|---|---|---|
| First described | 1977 | Reported as a component of thymosin fraction 5 |
| Sequence length | 28 amino acids | N-terminal residue is acetylated |
| Net charge at neutral pH | Negative | Reflects a high proportion of acidic residues |
| Principal studied uses | Chronic hepatitis B and vaccine adjuvant | Research uses outnumber approved indications |
| Regulatory status | Approved in a limited number of countries | Not approved in the United States or most of Europe |
胸腺素α1（thymosin alpha 1，Tα1）是一种由28个氨基酸组成的酸性肽，N端被乙酰化，分子量约为3108道尔顿。该肽最早从牛胸腺组织提取物中分离，属于胸腺素组分5的一个成分。其序列在不同哺乳动物中高度保守，提示其具有基本的生物学功能。名称中的“α1”指其在电泳中的迁移位置，并非表示亚型编号。它既存在于胸腺，也存在于脾脏和淋巴结等免疫组织。
20世纪70年代，研究者从胸腺提取物中纯化出多种小肽，Tα1是其中被较早表征的一种。最初的制备依赖组织匀浆和层析步骤，产量低且成分复杂。随着固相肽合成技术成熟，实验室和工业界能够生产与天然序列一致的合成版本。合成肽的纯度可达95%以上，并可通过反相高效液相色谱和质谱进行鉴定。这一转变使研究不再依赖动物胸腺来源。
市售的胸腺素α1通常以冻干粉形式提供，溶解后用于注射。其氨基酸组成包括多个酸性残基，因此在中性pH下带负电荷。该肽可溶于水和生理盐水，但在有机溶剂中溶解度有限。储存条件通常为冻干状态下负20摄氏度，溶解后需冷藏并避免反复冻融。常见的同义词包括胸腺肽α1、thymalfasin和Tα1。
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
== External links == 16S rRNA, BioMineWiki Archived 2019-04-27 at the Wayback Machine Ribosomal Database Project II Archived 2020-08-19 at the Wayback Machine Ribosomal+RNA at the U.S. National Library of Medicine Medical Subject Headings (MeSH) SILVA rRNA Database Project (also includes Eukaryotes (18S) and LSU (23S/28S)) Video: rRNA: sequence, function & synthesis Halococcus morrhuae (archaebacterium) 5S rRNA
== Sources == Bingham, Jonathan Brewster (1953). Shirt-Sleeve Diplomacy: Point 4 in Action. John Day & Co. Brown, William Adams Jr.; Opie, Redvers (1953). American Foreign Assistance. Washington, DC: The Brookings Institution. Butterfield, Samuel Hale (2004). U.S. Development Aid – An Historic First: Achievements and Failures in the Twentieth Century. Westport, CN: Praeger. ISBN 0-313-31910-3. Glick, Philip M. (1957). The Administration of Technical Assistance: Growth in the Americas. Chicago: University of Chicago Press. Haviland, H. Field (1958). "Foreign Aid and the Policy Process: 1957". The American Political Science Review. 52 (3): 689–724. doi:10.2307/1951900. JSTOR 1951900. S2CID 144564474. Hayes, Samuel J., ed. (1971). The Beginnings of American Aid to Southeast Asia: The Griffin Mission of 1950. Lexington, MA: Heath Lexington Books. Jolly, Richard; Emmerji, Louis; Ghai, Dharam; Lapeyre, Frederic (2004). UN Contributions to Development Thinking and Practice. Bloomington: Indiana University Press. Kaufman, B. Ira (1982). Trade and aid : Eisenhower's foreign economic policy, 1953–1961. Baltimore, MD: Johns Hopkins University Press. p. 82. ISBN 978-0-8018-2623-8. Nowels, Larry Q. (February 1987). Economic Security Assistance As a Tool of American Foreign Policy: The Current Dilemma and Future Options (PDF) (Report). National War College. Archived from the original (PDF) on 2017-10-11. Retrieved 2017-06-20 – via Development Experience Clearinghouse. Ruttan, Vernon W. (1996). United States Development Assistance Policy: The Domestic Politics of Foreign Economic Aid.
=== Fa–Fi === Leone N. Farrell (1904–1986). Canadian biochemist and microbiologist at Connaught Laboratories (Toronto) who discovered a way to isolate live virus in bulk quantities, sufficient for producing the polio vaccine. Richard D. Feinman (b. 1940). American biochemist and medical researcher at SUNY Downstate Medical Center, known for research on the Atkins Diet, and on application of thermodynamics to nutrition. David Sidney Feingold (1922–2019). American biochemist at the University of Pittsburgh known for research on carbohydrates. David Fell (b. 1947). British biochemist at Oxford Brookes University who has contributed to the development of systems biology. Author of Understanding the control of metabolism. John D. Ferry (1912–2002). Canadian-American biochemist at the University of Wisconsin–Madison noted for development of surgical products from blood plasma. Member Natl. Acad. Sci. USA. Alan Fersht FRS (b. 1943). British chemist and biochemist at the University of Cambridge, known for enzyme kinetics and protein folding. Foreign Associate Natl. Acad. Sci. USA. Edmond H. Fischer FRS (foreign member) (1920–2021). Swiss American biochemist at the University of Washington known for protein kinases and phosphatases. Nobel Prize in Physiology or Medicine (1992). Member Natl. Acad. Sci. USA.
Sources: en.wikipedia.org
The fish is beheaded, eviscerated and cut flat by removing the spine, often on board the boat or ship (this is feasible with whitefish, whereas it would not be with oily fish). It is then salted and dried ashore. Traditionally the fish was sun-dried on rocks or wooden frames, but modern commercial production is mainly dried indoors with electrical heating. It is sold whole or in portions, with or without bones.
doi:10.1126/scitranslmed.aaf1059. PMC 5505565. PMID 27225182. Park, J; Wetzel, I; Marriott, I; Dréau, D; D'Avanzo, C; Kim, D-Y; Tanzi, RE; Cho, H (2018). "Neuron-Glia Interactions Recapitulated in a 3D Organotypic Human Alzheimer's Disease Brain Model". Nature Neuroscience. 21 (7): 941–951. doi:10.1038/s41593-018-0175-4. PMC 6800152. PMID 29950669. Eimer, WA; Kumar, D; Kumar, N; Breakefield, XO; Tanzi, RE; Moir, RD (2018). "Alzheimer's Disease-Associated b-Amyloid Is Rapidly Seeded by Herpesviridae to Protect against Brain Infection". Neuron. 99 (1): 1–9. doi:10.1016/j.neuron.2018.06.030. PMC 6075814. PMID 30001512.
There are damehoods for actress Imelda Staunton, fashion designer Anya Hindmarch and artist Tracey Emin, while former Prime Minister Gordon Brown is made a Companion of Honour. 15 June – Trooping the Colour, the King's birthday parade, takes place. 16 June – Euro 2024: In their first game of the tournament, England win 1–0 against Serbia. 17 June The actor Sir Ian McKellen is taken to hospital after falling off stage during a performance of Player Kings at London's Noël Coward Theatre. Data shows that the London Stock Exchange has become the most valuable in Europe for the first time since 2022. The BBC's Panorama documentary series shows recordings of instances of abuse at a school for children with special educational needs in Wallasey, Merseyside. 18 June – A review conducted into the first Stephen Lawrence murder investigation concludes that four retired detectives who worked on the case will not face any criminal charges over their actions during the investigation. 19 June Figures show inflation fell to the Bank of England's target of 2% in the year to May 2024, down from 2.3% the previous month, and the first time it has been at 2% since July 2021. A woman who accused a therapist of raping and sexually assaulting her at his clinic in London's Belsize Park in 2016 is awarded £200,000 in damages following a civil case she brought against him, after the Crown Prosecution Service did not pursue the case. Figures show that 880 migrants crossed the English Channel on 18 June, setting a new record for daily crossings.
Sources: en.wikipedia.org
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.
Authorization is limited to a small number of countries and covers specific indications such as chronic hepatitis B and vaccine adjuvant use. Availability and labelling differ by jurisdiction.
Most reviews describe it as an immunomodulatory agent with an uncertain clinical effect. They generally call for larger, better-controlled trials before firm conclusions are drawn.
It corresponds to the first 28 amino acids of thymosin beta-4, a larger protein found in many tissues. The fragment is acetylated at its N-terminus and is produced synthetically for research and pharmaceutical use. Synthetic and natural forms share the same sequence.